ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0736

Treatment of IgG4-Related Disease (IgG4-RD) with Elotuzumab, an Inhibitor of SLAM-F7: Report of a Phase 2 Clinical Trial

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0345

Treatment Patterns and Glucocorticoid Burden of Dermatomyositis Patients: A Cohort Study in the University of Pittsburgh’s Myositis Registry

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0663

Treatment Patterns and the Prevalence of Kidney Biopsy-Confirmed LN in Patients with SLE and Proteinuria: A Multicenter Cohort Study

SLE – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0509

Trends in Initiation of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially-Insured US Adults, 2001-2021

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0280

Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0397

Trends in New Use of Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001-2022

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0625

Trends, Outcomes, and Predictors of Mortality in Patients with SLE Hospitalized for Influenza

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0650

Tubulointerstitial Inflammation Predicts Tubular Atrophy, Fibrosis, and Renal Function Loss in Lupus Nephritis

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0381

Two- and 3-Year Outcomes of the Childhood Arthritis and Rheumatology Research Alliance FROST Study of New-onset Systemic JIA Treatment

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0001

Type I Interferon and Anifrolumab Effects on Bone Marrow and Blood Plasma Cells in Systemic Lupus Erythematosus

B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 0220

Ultrasound-assessed Dactylitis as a Biomarker in the Early Diagnosis of Psoriatic Arthritis

Imaging of Rheumatic Diseases Poster I: Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 0126

Underdiagnosis Prediction Fingerprint for Antiphospholipid Syndrome Derived from Electronic Health Record Data

Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0676

Understanding the Patient Burden of Lupus: Insights from Multi-Faceted Ethnography Research

SLE – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0471

Understanding the Role of the Complement System in Insulin Resistance and Metabolic Syndrome in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0217

Understanding Treatment Goals and Factors Influencing Decisions About Clinical Trial Participation in Lupus Patients from Diverse Backgrounds

Health Services Research – ACR/ARP Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].